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Cancer accounts for roughly 7 percent of Kenyan mortality, making
it the country's third leading cause of death [1]. Available statistics
indicate that 70–80 percent of cancer cases in Kenya are first diagnosed
only in later stages [2]. Despite its high prevalence and the care needed
to treat late-stage cancer, Kenya has few facilities and qualified
healthcare workers (HCWs) that are dedicated to cancer treatment. In
periods of a pandemic like COVID-19, both patients and HCWs may be
at an additional risk of contracting the disease if tailored measures and
strategies are not implemented for continuity of services.
Studies conducted in China [3]; Italy [4], U.S.A., Canada, and Spain
[5] and the United Kingdom [6] confirm a higher risk for contracting
and dying from COVID-19 in vulnerable individuals particularly those
with such underlying health issues as chronic respiratory, cardiovas-
cular, diabetes; or active cancer. These findings indicate the urgent
need to institute measures known to reduce the risk of contracting
COVID-19 while ensuring that there is continuity of care for cancer
patients.
In Kenya, the few cancer facilities are located in urban centers. Few
Kenyan rural hospitals, where 72 % of the Kenyan population live, have
no dedicated cancer facilities. Rural cancer patients are, therefore,
obliged to travel to urban centers for treatment, which can be inter-
mittent and delivered over an extensive period. Poverty, lack of trans-
port, poor roads, packed cancer wards, and lack of a place to stay in the
city all combine to deprive many very ill cancer patients timely and
appropriate medical treatment [7]. Additionally, tthose that do get
treated may have trouble with complex drug regimens. Side effects that
lower their immunity make already ill cancer patients still more vul-
nerable to infections pathogens, and now, SARS-CoV-2.
Seeking to contain the spread of COVID -19, Kenya's Ministry of
Health (MOH) enacted measures at the end of March 2020 to enforce
social distancing. From April through July 2020, the government has
imposed a strict curfew prohibiting Kenyans from leaving their houses
from 7 P.M. to 5 A.M. in the first two months, and later from 9 P.M. to
4:00 A.M [8]. Additional measures include a ban on travel from all rural
areas and county cities to the capital Nairobi, which contains the vast
majority of cancer services. The government's one-size-fits-all COVID-
19 containment strategy fails to factor in the special needs of citizens
made vulnerable by compromised immunity who need continuous and
intensive medical care. As a result, the country's few cancer facilities
are open for only a few hours in a day; fewer patients are seen each day,
and specialized cancer health care workers are even more scarce.
Likewise, a total lockdown contains no provisions for patients who need
to travel to care facilities and live away from home to continue their
treatment.
In Kenya, COVID-19 has become a highly stigmatized disease.
People have little information about what to do to protect themselves,
and police regularly beat up citizens found outside during curfew. Local
newspapers report those deceased are being buried hurriedly under
cover of night, and those close to an infected person are stigmatized and
likely to be victimized. Moreover, cancer, like COVID-19, is highly
stigmatized. Along with the fear that they will catch COVID-19 on the
way to a medical facility, in hospital, in their lodgings away from home,
Kenya's cancer patients also have to fear ostracism in the communities
where they live. As the growing number of COVID-19 cases swamps
Kenya's already inadequate health care system, these attitudes, added
to cancer patients' elevated risk for COVID infection, may cause the
country's few oncology nurses to fear to treat their patients.
Oncology specialists are faced with questions around how best to
take care of cancer patients, ensuring they get timely antitumor treat-
ment as well as alleviating side effects and other distressing symptoms
while preventing exposure to COVID – 19. The Kenya government in
the interim guidelines developed by the Ministry of Health (MOH) re-
commend postponement of elective surgeries where COVID-19 de-
mands on personnel and supplies strain service provision. The directive
also gave vague guidance on the treatment of gynecological cancers and
the interim guidelines developed by the Ministry of Health (MOH) does
not advise on the management of cancer patients [9]. In contrast to the
government guidelines, the Kenya Society of Hematology and Oncology
issued a position statement calling for the resumption of cancer surgery
for both new and ongoing patients [10]. Lack of clear messages from
the Ministry of Health has confused cancer providers prompting treat-
ment centers to develop their guidelines. For instance, private hospitals
in the cities have developed their protocols and initiated patients' tel-
econsultations, which primarily attend to the middle-class patient. The
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lack of guidelines has left impoverished patients at a heightened risk,
particularly in patients currently receiving or recently having received
chemo- or radiation therapy and those requiring bone marrow or cell
transplants.
In this unprecedented pandemic, we must strategically approach
cancer care to ensure that COVID-19 does not further exacerbate in-
equalities within the health system. Lack of nationally standardized
guidelines for the treatment and management of cancer will fail cancer
patients. Therefore, local context research on the status of cancer pa-
tients and mitigation strategies is urgently needed to reduce COVID-19
adverse outcomes and to inform policy. This crisis may also be the
opportune time to integrate cancer care services as part of existing
primary care services, particularly at the county level. Longterm, the
Kenyan government needs to implement the National Cancer Control
Strategy 2017–2022, which plans to decentralize services and improve
cancer surveillance.
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